Literature DB >> 22879828

Seroprevalence of hepatitis e virus varies considerably among chinese provinces.

Chen Dong1, Xing Dai, Jiuhong Liang, Min Dong, Jihong Meng.   

Abstract

BACKGROUND: Hepatitis E is a common infection in China, but few studies have been carried out to compare regional and ethnic factors in its prevalence.
OBJECTIVES: To characterize the seroprevalence of anti-HEV IgM and IgG in the general population of 11 Chinese provinces and in the people from different ethnic minorities.
MATERIALS AND METHODS: Sera from 14208 people including 723 people from four ethnic minorities were screened for anti-HEV IgM and IgG by enzyme-linked immunosorbent assay (ELISA). For the anti-HEV IgM positive samples, reverse transcription-polymerase chain reaction (RT-PCR) was carried out for the detection of HEV RNA.
RESULTS: The overall prevalence of anti-HEV IgG was 19.7%. The highest rate was 35.7% in Guizhou, while the lowest rate was 5.5% in Shanxi. Significantly higher rates were found among males compared to females in Hebei and Hunan province, and among females compared to males in Chongqing and Shannxi. In Guizhou, the prevalence rates among the Buyi, Miao, Shui and Han ethnic groups were 41.8%, 32.0%, 37.5% and 34.7%, respectively, which were not significantly different. The results also showed that the anti-HEV IgG detection rates increased with age for each ethnic group. Additionally, four samples were tested positive for anti-HEV IgM but HEV RNA was not detectable.
CONCLUSIONS: HEV prevalence varies considerably among Chinese provinces. Thus, prevention and control programs including vaccination could be specifically targeted to people living in regions with relatively higher prevalences.

Entities:  

Keywords:  China; Hepatitis E; Seroprevalence

Year:  2012        PMID: 22879828      PMCID: PMC3412555          DOI: 10.5812/hepatmon.6194

Source DB:  PubMed          Journal:  Hepat Mon        ISSN: 1735-143X            Impact factor:   0.660


1. Background

Hepatitis E virus (HEV) is a single-strand, non-enveloped virus with an RNA genome of ~7.5 kb in length. It is the only member of the genus Hepevirus in the family Hepeviridae [1]. Hepatitis E, caused by HEV, is responsible for nearly 50% of cases of acute viral hepatitis in developing countries of Asia, Africa and Latin America where sanitary conditions are suboptimal [2][3][4]. Acute infection primarily affects young adults between 15 and 40 years of age and is generally mild, but the mortality rate is particularly high (10% - 40%) among pregnant women [5]. Chronic HEV infection, although rare, has been reported in immune suppressed people [6][7][8][9]. The epidemiology of HEV is complex [10][11][12]. Studies in endemic regions indicate high seroprevalence rates ranging from 15% to 60% [10]. In China, hepatitis E epidemics have largely been associated with consumption of focally contaminated water [13]. There is gathering evidence to suggest that HEV is also a zoonosis [14][15][16]. Although HEV infection with eating raw or inadequately cooked meat and offal from dear, boars and pigs has been reported [17][18][19], these have not been reported in China. Several studies have been carried out to estimate the seroprevalence of HEV in Chinese population [20][21][22][23][24][25].Relatively high seroprevalence rates were found in pig farmers, old people and people living in rural areas, which contrast with general population, children and people who lived in urban districts [21][22][24]. These studies were, however, carried out in populations confined to relatively small locales.

2. Objectives

The present study is an attempt to investigate the anti-HEV IgM and IgG in the general population of 11 Chinese provinces. Furthermore, for one province, where the highest prevalence rate was observed, we also included people belonging to minority ethnic groups.

3. Materials and Methods

3.1. Subjects

The study population consisted of 14208 apparently healthy people. These people, were community survey participants came from 11 provinces, include Hebei (n = 1374), Shanxi (n = 786), Beijing (n = 500), Jilin (n = 1177), Jiangsu (n = 1941), Anhui (n = 1529), Chongqing (n = 797), Hunan (n = 2181), Henan (n = 1866), Shannxi (n = 870) and Guizhou (n = 1187). In Guizhou, the following minority ethnic groups were studied: Miao (n = 225), Shui (n = 404), Buyi (n = 91) and Yi (n = 3); the remaining belongs to Han, which is the predominant ethnic group in China.

3.2. Ethical Considerations

This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association and was reviewed and approved by the Research Ethics Committee of Southeast University, China.

3.3. Serum Sampling

Serum samples were collected from June 2006 to June 2008 and stored at -70˚C until analyzed.

3.4. Detection of Antibodies Against HEV

The protocols used for detection of anti-HEV IgG and IgM were determined by an indirect (sandwich) enzyme immunoassay developed by Meng et al. with slightly modification [21]. Briefly, polystyrene plates were coated with antigens and stored at 4˚C until use. Test sera, with a 1:20 dilution, were added into the wells and incubated at 37˚C for 45 minutes. After washing, horseradish peroxidase-labeled goat-anti-human IgG or IgM was added to each well and then incubated at 37˚C for 45 minutes. The plates were washed five times with wash buffer after this incubation. After washing, TMB was added and incubated for 15 min. The reaction was stopped by adding H2SO4. The absorbance was read at 450 nm. The cutoff values for the assay of anti-HEV IgG and IgM were set at 0.252 and 0.386, respectively.

3.5. Detection of HEV RNA

For the anti-HEV IgM positive samples, reverse transcription-polymerase chain reaction (RT-PCR) was carried out for detection of HEV RNA. HEV RNA was purified from 100 µl serum, reverse transcribed, and then subjected to nested PCR as described previously [14]. Amplicons were separated by agarose gel electrophoresis with size markers and visualized by ethidium bromide fluorescence.

3.6. Statistical Methods

Chi-Square tests were used to compare the anti-HEV positive proportions between different groups. Statistical analysis was carried out by using SPSS version 15.0 for Windows.

4. Results

4.1. Prevalence of Anti-HEV IgG and IgM in Chinese General Population

In total, 14208 serum samples originating from people living in 11 provinces in China were collected. Serum samples were tested for anti-HEV IgG and IgM antibodies by using an indirect ELISA as described in materials and methods. The overall prevalence of anti-HEV IgG was 19.7%, 20.1% in males, and 19% in females, with no significant difference between sexes. For anti-HEV IgM detection, positivity was determined in four samples. Three male samples were from Jiangsu [2] and Hunan [1]. And the one female sample was from Anhui province. However, HEV RNA could not be isolated from these four samples by RT-PCR.

4.2. Seroprevalence of Anti-HEV IgG in Different Provinces

As shown in Figure 1, the detection rates of anti-HEV IgG varied among the Chinese provinces. The highest prevalence was 35.7%, in Guizhou, and the lowest was 5.5%, in Shanxi province. The seroprevalence in Jilin, Hebei, Anhui, Beijing and Henan ranged from 10% to 20% while those in Hunan, Jiangsu, Chongqing and Shannxi ranged from 20% to 30%. Significantly higher prevalences in males compared to females were observed from Hebei (13% vs. 7.6%, respectively, P = 0.001) and Hunan province (24.3% vs. 19.6%, respectively, P = 0.009). By contrast, higher prevelances among women compared to men were observed in Chongqing (20.9% vs. 31.8%, respectively, P = 0.0001) and in Shannxi province (23.5% vs. 31.79%, respectively, P = 0.007). In the other seven provinces, there were no significant associations in prevalences between sexes (Table 1).
Figure 1

A Map Indicating Different Seroprevalence of HEV Among Provinces in China

Table 1

Seroprevalence of Anti-HEV in 11 Provinces, China a

ProvinceMaleFemaleTotal of Each Province
HEV IgG Positive, No. (%)HEV IgG Negative, No.Total, No.HEV IgG Positive, No. (%)HEV IgG Negative, No.Total, No.HEV IgG Positive, No. (%)HEV IgG Negative, No.Total, No.
Jilin74 (11)60067453 (10.5)450503127 (10.8)10501177
Hebei107 (13.1) b71382042 (7.6)512554149 (10.8)12251374
Anhui125 (14.2)75688180 (12.4)568648205 (13.4)13241529
Beijing47 (19)20024740 (15.8)21325387 (17.4)413500
Henan212 (19.6)8701082164 (20.9)620784376 (20.2)14901866
Hunan310 (24.4) c9631273178 (19.6)730908488 (22.4)16932181
Jiangsu246 (24.7)750996209 (22.1)736945455 (23.4)14861941
Chongqing96 (20.9)d364460107 (31.8)230337203 (25.5)594797
Shannxi113 (23.5) e367480124 (31.8)266390237 (27.2)633870
Guizhou266 (37.6)441707157 (32.7)323480423 (35.7)7641187
Total1614 (20.1)640180151179 (19)501461932793 (19.7)1141514208

a Chi-Square Tests were used to compare the anti-HEV positive proportions between males and females

b Male vs. Female: x(2)=10.223, P = 0.001

c Male vs. Female: x(2)=6.880, P = 0.009

d Male vs. Female: x(2)=12.132, P = 0.000

e Male vs. Female: x(2)=7.359, P = 0.007

A Map Indicating Different Seroprevalence of HEV Among Provinces in China a Chi-Square Tests were used to compare the anti-HEV positive proportions between males and females b Male vs. Female: x(2)=10.223, P = 0.001 c Male vs. Female: x(2)=6.880, P = 0.009 d Male vs. Female: x(2)=12.132, P = 0.000 e Male vs. Female: x(2)=7.359, P = 0.007

4.3. Seroprevalence of Anti-HEV IgG in the Minorities

In the present study, the samples were originating from Guizhou province included five different minorities. The seroprevalence of anti-HEV IgG among Chinese ethnic minorities has also been analyzed. As seen in Table 2, the overall prevalence was 41.8%, 32%, 37.5% and 34.7% in Buyi, Miao, Shui and Han ethnic groups, respectively, despite the fact, these differences were not significant. There was also no significant difference between men and women in four different ethnic groups. The anti-HEV IgG detection rates increased with age for each ethnic group. Although these age-wise differences were not statistically significant in the Buyi, Miao and Han ethnic groups, the difference in the Shui group was also significant.
Table 2

Seroprevalence of Anti-HEV in Minorities, China a

MaleFemaleTotal
Ethnic GroupsbAge, ycAnti-HEV Positive, No. (%)Anti-HEV Negative, No.Total, No.Anti-HEV Positive, No. (%)Anti-HEV Negative, No.Total, No.Anti-HEV Positive, No. (%)Anti-HEV Negative, No.Total, No.
Buyid≤ 184 (40)6101 (20.0)565 (31.2)1116
Buyi18~6015 (42.9)203511 (40.7)162726 (41.9)3662
Buyi> 604 (50)483 (60.0)257 (53.8)613
BuyiTotal23 (43.4)305315 (39.5)233838 (41.8)5391
Miaoe< 189 (31.0)20294 (20.0)162013 (26.5)3649
Miao18~6029 (34.9)548322 (31.9)476951 (33.6)101152
Miao> 604 (40.0)6104 (28.6)10148 (33.3)1624
MiaoTotal42 (34.4)8012230 (29.1)7310372 (32.0)153225
Shuif< 1819 (24.4)59788 (23.5)263427 (24.1)85112
Shui18~6061 (41.8)8514637 (38.5)599698 (40.5)144242
Shui> 6020 (48.8)21416 (66.7)3926 (52.0)2450
ShuiTotal100 (37.7)16526551 (36.7)88139151 (37.5)253404
Hang< 1812 (26.7)33457 (25.0)212819 (26.0)5473
Han18~6068 (38.6)10817642 (30.7)95137110 (35.1)203313
Han> 6020 (44.4)254512 (36.4)213332 (41.0)4678
HanTotal100 (37.6)16626661 (30.8)137198161 (34.7)303464

a Chi-Square Tests were used to compare the anti-HEV positive proportions between males and females in different age groups.

b No significant difference among four ethnic groups (x2 = 3.591, P > 0.05)

c Chi-square test for trend was used to analyze the trend change of the anti-HEV positive proportions from group < 18 years to group 60 years old and above.

d x2 = 1.489, P > 0.05

e x2 = 3.702, P = 0.054

f x2 = 0.586, P > 0.05

g x2 = 13.741, P < 0.001.

a Chi-Square Tests were used to compare the anti-HEV positive proportions between males and females in different age groups. b No significant difference among four ethnic groups (x2 = 3.591, P > 0.05) c Chi-square test for trend was used to analyze the trend change of the anti-HEV positive proportions from group < 18 years to group 60 years old and above. d x2 = 1.489, P > 0.05 e x2 = 3.702, P = 0.054 f x2 = 0.586, P > 0.05 g x2 = 13.741, P < 0.001.

5. Conclusions

We conducted a large population-based serosurvey to determine the prevalence of HEV infection in China. Geographically, the 11 provinces sampled in this study nearly occupy 0.33 portion of China population. The overall prevalence was 19.7%. Previous studies, conducted in eastern and northeastern China, revealed that the anti-HEV-positive rate was about 20% to 50 % [21][24]. This difference could have arisen because of differences in the study sample sizes or may reflect true regional differences. Our findings, representing 11 provinces, revealed markedly different rates among the provinces, ranging from 5.47% to 35.7%. This disparity suggested that the extent of exposure to HEV varied significantly among different provinces. Factors explaining these differences could include differences in living and sanitary conditions. We included a study of the sero epidemiology of HEV in Chinese ethnic minorities. Besides the Han group, Guizhou Province has more than 10 ethnic minorities. We observed that, among Miao, Shui and Buyi groups, the HEV seroprevalence rates were similar to Han in Guizhou province, which suggests that the four groups studied shared the same risk factors for HEV infection. The prevalence rate in Han group in Guizhou was significantly higher than the rates observed in other provinces studied, where the Han ethnic group is predominant. As Guizhou is relatively underdeveloped compared to other provinces, its low economic status, high crowding, abundant water resources and inadequate water treatment in some regions of this province may contribute to its higher endemicity. The data from the previous studies reported that HEV seropositivity rate varied considerably in northeast China [24][26]. In one paper, the overall prevalence of HEV was 47.7 % (143/300) [26]. This rate appears higher than 10.8% we observed in Jilin, which is also located in the northeast China. In another report from a study in Heilongjiang, Jilin and Liaoning provinces, the prevalence rates were between 4.1% to 30% in the general population [24]. The reason for the discrepancy between our data from Jilin and those from these 2 studies may be due to differences in the sensitivity and specificity of anti-HEV IgG assays employed [27][28]. Furthermore, the contribution of sampling errors cannot be excluded. In summary, the overall anti-HEV seroprevalence rate among 11 Chinese provinces was 19.7%. The rates varied significantly in general population of different provinces in China, and in Guizhou, where the prevalence was highest, the rates were not significantly different among four ethnic groups sampled. Thus, prevention and control programs including vaccination could be specifically targeted to people living in regions with relativity higher prevalences.
  28 in total

1.  Severe hepatitis E virus infection after ingestion of uncooked liver from a wild boar.

Authors:  Hiroyuki Matsuda; Katsuo Okada; Kazuaki Takahashi; Shunji Mishiro
Journal:  J Infect Dis       Date:  2003-09-15       Impact factor: 5.226

2.  Consumption of wild boar linked to cases of hepatitis E.

Authors:  Yoko Tamada; Koji Yano; Hiroshi Yatsuhashi; Osami Inoue; Fumihiro Mawatari; Hiromi Ishibashi
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

3.  Hepatitis E and cholera outbreak in Kathmandu.

Authors:  Sharan Prakash Sharma
Journal:  CMAJ       Date:  2006-10-10       Impact factor: 8.262

4.  Investigation of viral hepatitis E outbreak in a town in Haryana.

Authors:  Shankar Prinja; Subrat Kumar; G M M Reddy; R K Ratho; Rajesh Kumar
Journal:  J Commun Dis       Date:  2008-12

5.  Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls.

Authors:  Björn Olsen; Diana Axelsson-Olsson; Anders Thelin; Ola Weiland
Journal:  Scand J Infect Dis       Date:  2006

6.  Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group.

Authors:  E E Mast; M J Alter; P V Holland; R H Purcell
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

Review 7.  Epidemiology of hepatitis E in China.

Authors:  H Zhuang; X Y Cao; C B Liu; G M Wang
Journal:  Gastroenterol Jpn       Date:  1991-07

8.  Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy.

Authors:  M S Khuroo; S Kamili
Journal:  J Viral Hepat       Date:  2003-01       Impact factor: 3.728

9.  Epidemiology of hepatitis E in Northeastern China, South Korea and Japan.

Authors:  Miyuki Taniguchi; Soo Ryang Kim; Shunji Mishiro; Kazuaki Takahashi; Myung Hee Shin; Haesun Yun; Man Suk Park; Zhong Min Li; Mi Kyung Kim; Jinnv Fang; Yoshitake Hayashi
Journal:  J Infect       Date:  2009-02-26       Impact factor: 6.072

10.  Zoonotic transmission of hepatitis E virus from deer to human beings.

Authors:  Shuchin Tei; Naoto Kitajima; Kazuaki Takahashi; Shunji Mishiro
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

View more
  8 in total

Review 1.  Hepatitis E virus infection: Epidemiology and treatment implications.

Authors:  Ga Young Lee; Kittiyod Poovorawan; Duangnapa Intharasongkroh; Pattaratida Sa-Nguanmoo; Sompong Vongpunsawad; Chintana Chirathaworn; Yong Poovorawan
Journal:  World J Virol       Date:  2015-11-12

2.  Hepatitis E seroprevalence among blood donors: A pilot study from Western India.

Authors:  Maitrey D Gajjar; Nidhi M Bhatnagar; Rajesh V Sonani; Shweta Gupta; Tarak Patel
Journal:  Asian J Transfus Sci       Date:  2014-01

3.  Binding Preference of Anti-HEV Antibodies in Sera Collected in Algeria for Antigens Derived From HEV Genotype 1‏.

Authors:  Nouredine Behloul; Min Zhang; Jihong Meng
Journal:  Hepat Mon       Date:  2016-07-20       Impact factor: 0.660

4.  HEV prevalence and potential risk factors in a large multi-ethnic youth cohort in China.

Authors:  Huixia Li; Yinxia Zhang; Zhongren Ma; Zewen Liu; Aqsa Ikram; Lijiang Liu; Guoqin Zhao; Qiuwei Pan; Zulqarnain Baloch
Journal:  Virol J       Date:  2021-01-06       Impact factor: 4.099

5.  The prevalence of hepatitis E virus infections among swine, swine farmers and the general population in Guangdong Province, China.

Authors:  Huanbin Liang; Shuo Su; Shengchao Deng; Honglang Gu; Fangxiao Ji; Lifang Wang; Chumin Liang; Heng Wang; Guihong Zhang
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

6.  Hepatitis E virus serosurvey among pet dogs and cats in several developed cities in China.

Authors:  Huanbin Liang; Jidang Chen; Jiexiong Xie; Long Sun; Fangxiao Ji; Shuyi He; Yun Zheng; Chumin Liang; Guihong Zhang; Shuo Su; Shoujun Li
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

7.  Anti-Hepatitis E Antibody in Hemodialysis Patients in Isfahan, Iran: Prevalence and Risk Factors.

Authors:  Seyed Moayed Alavian; Behrooz Ataei; Ali Ebrahimi; Omid Pirhaji; Roya Azad; Behrooz Olya; Amir Mohammad Ataei
Journal:  Hepat Mon       Date:  2015-09-08       Impact factor: 0.660

8.  Low seroprevalence of hepatitis E virus infection in pregnant women in Yunnan, China.

Authors:  Fen Huang; Tianwu Ma; Li Li; Weikun Zeng; Shenrong Jing
Journal:  Braz J Infect Dis       Date:  2013-09-19       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.